MX2025001384A - Forma cristalina de derivado triciclico fusionado y metodo de preparacion - Google Patents

Forma cristalina de derivado triciclico fusionado y metodo de preparacion

Info

Publication number
MX2025001384A
MX2025001384A MX2025001384A MX2025001384A MX2025001384A MX 2025001384 A MX2025001384 A MX 2025001384A MX 2025001384 A MX2025001384 A MX 2025001384A MX 2025001384 A MX2025001384 A MX 2025001384A MX 2025001384 A MX2025001384 A MX 2025001384A
Authority
MX
Mexico
Prior art keywords
crystal form
preparation
fused tricyclic
tricyclic derivative
derivative
Prior art date
Application number
MX2025001384A
Other languages
English (en)
Inventor
Xiaoming Su
Zhiya Li
Yimin Hu
Gujun Xu
Tingting Shang
Jie Wang
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2025001384A publication Critical patent/MX2025001384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción se refiere a una forma cristalina de un derivado tricíclico fusionado y a un método de preparación, y se refiere específicamente a una forma cristalina de un 5 compuesto (3S,4R)-4-((5-cloro-4-((S)-8-fluoro-2-(2-hidroxipropano-2-il)-3-metil-3,4-dihidro-5-oxa-1,2a-diazacenaftileno-6-il)pirimidina-2-il)amino)tetrahidro-2H-piran-3-ol, una sal farmacéuticamente aceptable del mismo, y a un método de preparación correspondiente.
MX2025001384A 2022-08-01 2025-01-31 Forma cristalina de derivado triciclico fusionado y metodo de preparacion MX2025001384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210915848 2022-08-01
PCT/CN2023/110180 WO2024027631A1 (zh) 2022-08-01 2023-07-31 一种稠三环类衍生物的晶型及制备方法

Publications (1)

Publication Number Publication Date
MX2025001384A true MX2025001384A (es) 2025-03-07

Family

ID=89848540

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025001384A MX2025001384A (es) 2022-08-01 2025-01-31 Forma cristalina de derivado triciclico fusionado y metodo de preparacion

Country Status (8)

Country Link
EP (1) EP4567040A4 (es)
JP (1) JP2025528074A (es)
KR (1) KR20250040728A (es)
CN (1) CN119522226B (es)
AU (1) AU2023319371B2 (es)
MX (1) MX2025001384A (es)
TW (1) TW202406912A (es)
WO (1) WO2024027631A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121399137A (zh) * 2023-07-27 2026-01-23 上海拓界生物医药科技有限公司 一种含氧稠三环衍生物及其制备方法和用途
WO2026158568A1 (zh) * 2025-01-24 2026-07-30 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的结晶形式、药物组合物及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818690B (zh) * 2016-07-26 2021-08-10 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
KR102543603B1 (ko) * 2016-12-22 2023-06-14 베타 파머수티컬 컴퍼니 리미티드 벤조이미다졸 유도체, 제조 방법 및 그것의 용도
CN118286225A (zh) * 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
CN113698391B (zh) * 2020-05-21 2023-06-06 上海拓界生物医药科技有限公司 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法
CN120682245A (zh) * 2021-02-03 2025-09-23 江苏恒瑞医药股份有限公司 稠三环类细胞周期蛋白-依赖性激酶抑制剂及其制备方法和医药用途
CN117486898A (zh) * 2022-08-01 2024-02-02 江苏恒瑞医药股份有限公司 一种稠三环类衍生物的晶型及制备方法

Also Published As

Publication number Publication date
AU2023319371A1 (en) 2025-03-06
JP2025528074A (ja) 2025-08-26
EP4567040A4 (en) 2025-11-12
AU2023319371B2 (en) 2026-07-16
CN119522226B (zh) 2026-08-11
EP4567040A1 (en) 2025-06-11
CN119522226A (zh) 2025-02-25
WO2024027631A1 (zh) 2024-02-08
TW202406912A (zh) 2024-02-16
KR20250040728A (ko) 2025-03-24

Similar Documents

Publication Publication Date Title
NZ599342A (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
WO2007023382A3 (en) Pyrimidine amino pyrazole compounds, potent kinase inhibitors
MXPA04003759A (es) Derivados de pirrolidin n-substituido como inhibidores de dipeptidil peptidasa iv.
WO2006106423A3 (en) Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EA201891463A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK)
NZ578876A (en) 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
EP4365179A3 (en) Novel rapamycin derivatives
TW200612936A (en) Indole derivatives
TW200736258A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MX2023006842A (es) Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
WO2005070884A3 (en) Heterocyclic compounds useful as growth hormone secretagogues
PH12021552533A1 (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
MY169232A (en) Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
MX2023004102A (es) Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo.
ZA202500857B (en) Compounds and methods for modulating her2
MX2025005861A (es) Sal farmaceuticamente aceptable de compuesto heterociclico que contiene nitrogeno, forma cristalina de la misma y metodo de fabricacion de la misma
IL277904B2 (en) History of indan for use in the treatment of pain and inflammation
WO2021226276A3 (en) Nampt modulators
WO2007083188A3 (en) Improved process for the preparation of an optically active 5h-pyrrolo [3,4-b] pyrazine derivative
TW200626158A (en) Naphthaline derivatives
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
WO2018127526A3 (en) Solid forms of [(1 s)-1 -[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
WO2006030211A3 (en) Acyclic sulphonamides